Drug intelligence / Profile preview

AD-221C

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-221C is an incrementally modified antihyperlipidaemic drug developed by Addpharma, a subsidiary of Yuhan, for the treatment of hypercholesterolemia. It has been evaluated in phase 3 clinical trials as an oral tablet administered once daily for 8 weeks in patients with primary hypercholesterolemia. The precise mechanism of action remains undefined, and it is not classified as a new molecular entity[1][2].

Beyond the preview

Go deeper on AD-221C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-221C.

Explore the full profile